全基因组的CRISPR-Cas9淘汰屏幕识别了DNMT1作为声波刺脑膜母细胞瘤中可服用药物的依赖性

Foteini Tsiami1,2, Chiara Lago3, Noemi Pozza3

  • 1Department of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Eberhard Karls University, Tübingen, Germany.

概括

向DNA甲基转移酶1 (DNMT1) 为Sonic hedgehog medulloblastoma (SHH-MB) 提供了一个新的治疗策略. 单独或与SMO抑制剂一起抑制DNMT1,有效地治疗SHH-MB模型并克服耐药性.